KU Leuven Department of Microbiology and Immunology, Rega Institute for Medical Research, Belgium.
Global Virus Network, GVN.
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):209-214. doi: 10.1177/2048872620922790. Epub 2020 May 4.
Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019.
治疗 2019 年冠状病毒病的方法迫切需要，以应对持续的严重急性呼吸综合征冠状病毒 2 大流行。抗病毒药物和免疫调节剂都有可能在 2019 年冠状病毒病的治疗中发挥作用。不幸的是，目前还没有批准用于治疗人类冠状病毒感染的药物。由于开发针对严重急性呼吸综合征冠状病毒 2 的新疗法需要数年时间，目前的重点是重新利用已批准或正在开发用于其他疾病的药物。已经进行了几项临床试验，或者目前正在进行临床试验，以评估这些药物的疗效。在这里，我们讨论了这些疗法治疗 2019 年冠状病毒病的潜力。
